Recombinant negative-strand RNA virus (I) comprises a viral genome with a mutation in the N, L or P gene that results in loss of replication capability without loss of transcription capability. Independent claims are also included for: (1) nucleocapsid (II) of (I)； (2) genome (III) of (I)； (3) DNA molecule (IV) coding for the genome or antigenome of (I)； (4) cell (V) containing (I), (III) or (IV)； (5) producing (I) by providing a cell transfected with a DNA molecule coding for (I) and optionally a heterologous gene product, and culturing the cell under conditions suitable for transcription of the DNA molecule； (6) multiplying (I) by providing a cell infected with (I) and culturing the cell under conditions suitable for multiplication of (I)； (7) pharmacuetical composition comprising (I), (II) or (III)； (8) use of a cell (VI) that stably expresses the N, L or P protein of a negative-strand RNA virus in a constitutive or inducible manner for producing or multiplying (I) (II) or (III). ACTIVITY : Virucide. MECHANISM OF ACTION : Vaccine； Ribozyme； Antisense oligonucleotide inhibitor； RNAi； RNA interference.
